Skip to main content
Premium Trial:

Request an Annual Quote

StemCells Completes SCS Acquisition

NEW YORK (GenomeWeb News) – StemCells today announced that it has completed its acquisition of UK-based Stem Cell Sciences for 2.65 million shares of its common stock and $700,000 in cash.

Based on the Tuesday closing price of StemCells' stock ($1.67), the deal is valued at around $4.4 million, lower than the $4.8 million estimated when the deal was signed in early March. SCS' shareholders overwhelmingly approved the deal last week at an extraordinary general meeting.

The acquisition provides Palo Alto, Calif.-based StemCells , which is focused on developing tissue-derived cellular products for therapeutic uses, with cell-based drug discovery technologies. Among the products StemCells gains through the deal are automated systems for production and manipulation of stem and progenitor cells, gene insertion technology for drug screening and for applications in cell and gene therapy, the SC Proven media formulation and reagent business, and SCS' licensing deals with firms, such as Merck and Millipore.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.